About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback | Follow Us 
Advanced search
The Official Scientific Journal of Delhi Ophthalmological Society
Role of Anti VEGF Agent in Management of Primary Pterygium
Abhinav Singh1, Sagarika Patyal2, Vinod K. Baranwal3, Gaurav Kapoor4
1Military Hospital Dimapur, Nagaland, India; 2Centre for Sight New Delhi, India; 3Military Hospital Jhansi, Uttar Pradesh, India; 4Base Hospital Delhi Cantt (BHDC) & Army College of Medical Sciences (ACMS), Delhi Cantt., New Delhi, India
Corresponding Author:
Maj (Dr) Abhinav Singh 
Ground Floor, House No. 420
Sector 80, Mohali, Punjab 140308,
Email id: docskool@gmail.com
Published Online: 01-NOV-2018
DOI: http://dx.doi.org/10.7869/djo.391
Objective: To assess the role of Anti VEGF agent in management of primary pterygium. 
Study Design: Prospective Study. 
Methodology: This prospective comparative study included twenty (20) eyes with primary nasal pterygium and off label use of a single dose of subconjunctival injection of Bevacizumab (0.05 ml, 
1.25 mg) injected in the body of pterygium. The vascularity, thickness and size (in cm2) was recorded at baseline and 08 weeks after injection. The main outcome measures were the change in size, vascularity and thickness. 
Result: There were 16 males (80%) and 04 females (20%), with a mean age of 41.5 yrs. There was no significant difference in the mean surface area of pterygium at different time intervals. However, the thickness and vascularity of the pterygium was significantly reduced. There was a significant difference in the pterygium grading by 2 masked observers at different times. At baseline, there were 14 (70%) grade II and 6 (30%) grade III pterygium. At 08 weeks post injection, there were 7 (35%) with grade I pterygium, 10 (50%) with grade II & 3 (15%) with grade III pterygium. No serious ocular or systemic side defects were observed. 
Conclusion: Single dose subconjunctival injection of bevacizumab resulted in regression of pterygium thickness and vascularity. However, local injection of bevacizumab showed no significant difference in the size of the pterygium at the end of 08 weeks. The long term effect of anti VEGF agent in the management of primary pterygium requires further evaluation.
Keywords : Bevacizumab, Vascular Endothelial Growth Factor, Pterygium
Article Options
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share